That's the whole root of Celgene / MMR agreement that is ultimate full pay day is based on whether FDA agrees to let Celgene use it in accelerating their own trials.
Incorrect. The FDA would not accelerate any Celgene trial based on data from previously failed or incomplete drug trials.
Tell ya what. I know an investor who knows every twitch that CELG makes, or has made in the past decade. I'll ask him the simple questions tomorrow: What was the purpose of the CELG MMRF agreement? Why did CELG need "data" from failed or incomplete drug trials for one of their upcoming drug trials 6 yrs ago? What is the current status of the 2010 agreement? Would CELG currently even need the data from 8 yrs ago? Is there any evidence CELG made any payments to MMRF, as a follow up to any initial payment of $800K claimed by MMRF? What were the milestone payments to be based on? Or is this horse long dead and decaying from the CELG perspective.
BTW - it's doubtful Roche, GSK, or one of the other players in the CD20 Ab field are too interested in 8 yr old data of failed drug trials. So much for the valuable data, and tons of future revenue.
The Jewel of the Mind is Colored with the Hue of what it Imagines